PhenoPath participates in numerous regional and national professional association meetings, trade shows, tumor boards and other events as featured speakers and show sponsors. In addition, PhenoPath invites nationally known speakers to speak at its conferences held in Seattle. Listed below are upcoming meetings and events.
At the PhenoPath Conference
Achim A. Jungbluth, M.D.
Department of Pathology
Memorial Sloan-Kettering Cancer Center
1275 York Avenue
New York, NY
PhenoPath, Thursday, January 25, 2018, 6:00PM (light dinner), 7:00PM (talk)
Achim Jungbluth, MD, PhD will present “How to set up an IHC protocol in the times of PD-L1 (without the need to consult a psychiatrist)” at the PhenoPath Conference at 7:00pm on Thursday, January 25, 2018. It promises to be an interesting and entertaining talk. Dr. Jungbluth will be giving another talk “Melanocyte Differentiation Antigens” at noon at PhenoPath, to which you are invited as well. Please inquire for more information.
Dr. Jungbluth is the Director of the IHC Developmental Lab in the Department of Pathology at Memorial Sloan Kettering Cancer Center (MSKCC) in New York, where his focus is the development, standardization and initialization of novel IHC protocols for patient care and translational research. For over twenty years, Dr. Jungbluth was Director of Pathology at the New York Branch of the Ludwig Institute for Cancer Research (LICR) at MSKCC, a renowned international cancer research foundation dedicated to discovery and development of immunological and biological-based cancer therapies. At the LICR, Dr. Jungbluth was leader in the seminal discovery, identification and characterization of tumor-associated antigens, development of therapeutic and diagnostic antibodies and other immunological therapies, which were the basis for some of the current established cancer immunotherapies.
Dr. Jungbluth received his MD/PhD at the University of Giessen and Wurzberg in Germany and performed his pathology training at the University Hospital of Mainz and Darmstadt, Germany.